Skip to Content

Nebivolol Pregnancy and Breastfeeding Warnings

Nebivolol is also known as: Bystolic

Nebivolol Pregnancy Warnings

Use is not recommended unless clearly needed AU TGA pregnancy category: C US FDA pregnancy category: C Comments: -If used during pregnancy, monitor placental blood flow and fetal growth -After birth, monitor for the signs and symptoms of beta blockade, generally present in the first 3 days.

Animal studies at dose levels associated with maternal toxicity have revealed small delays in sternal and thoracic ossification and reductions in litter size and weight [at 18 times the maximum recommended human dose (MRHD)]. Furthermore, use in late gestation and parturition increased gestation, fetal death and stillbirths, and decreased weight, litter size, and survival (at doses of 1.2 times the MRHD). Beta-adrenergic blocking agents have been shown to decrease placental perfusion which has been associated with growth retardation, premature and immature deliveries and fetal death. Due to limited data, if a beta-blocking agent is required, may consider another beta-1-adrenoreceptor blocker. There are no controlled data in human pregnancy. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected to causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.

See references

Nebivolol Breastfeeding Warnings

Use not recommended Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: Breastfed infants should be monitored for the signs and symptoms of beta blockade, for example, bradycardia, respiratory distress, and hypoglycemia.

Beta-adrenergic blocking agents, particularly lipophilic agents like this drug, have caused adverse events in breastfed newborns. In animal models, this drug is excreted into breastmilk and is expected to have moderate accumulation in the infant due to its high protein binding and long half-life.

See references

References for pregnancy information

  1. "Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals, St. Louis, MO.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  4. "Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals, St. Louis, MO.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.